14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FDMT vs MPLT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, MapLight Therapeutics, Inc. (MPLT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). FDMT carries a Unified Composite Score of 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas MPLT carries 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. MPLT 50.4/100 HOLD), MPLT captures the overall institutional head-to-head verdict (3–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -222.7% operating margin) and revenue trajectory (+0.0% vs. +4505.6% YoY).
Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FDMT vs MPLT. Trailing 12-month operating profitability (FDMT -222.7% vs MPLT 0.0%) and valuation multiples (FDMT N/M vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $392.9M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FDMT vs MPLT Key Questions & Quantitative Answers
As of Nov 16, 2026, MapLight Therapeutics, Inc. (MPLT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). FDMT carries a Unified Composite Score of 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas MPLT carries 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. MPLT 50.4/100 HOLD), MPLT captures the overall institutional head-to-head verdict (3–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -222.7% operating margin) and revenue trajectory (+0.0% vs. +4505.6% YoY). Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with MPLT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FDMT generates $96M in USD-normalized revenue versus N/A for MPLT. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MPLT.
FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus MPLT (-111.5% ROE) capital efficiency.
In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, MPLT carries 92.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.05β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.